DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,412,062 | -14.9% | 68,447 | +21.7% | 0.07% | -13.8% |
| Q2 2023 | $1,659,760 | +43.3% | 56,244 | +11.9% | 0.08% | +27.0% |
| Q1 2023 | $1,158,083 | +82.9% | 50,264 | +120.8% | 0.06% | +61.5% |
| Q4 2022 | $633,011 | -44.3% | 22,762 | -38.5% | 0.04% | -47.3% |
| Q3 2022 | $1,136,000 | +4.1% | 37,026 | -0.1% | 0.07% | +25.4% |
| Q2 2022 | $1,091,000 | -18.0% | 37,064 | -10.4% | 0.06% | +1.7% |
| Q1 2022 | $1,331,000 | -72.3% | 41,385 | -61.6% | 0.06% | -74.4% |
| Q4 2021 | $4,810,000 | -3.1% | 107,842 | +9.5% | 0.23% | -18.9% |
| Q3 2021 | $4,966,000 | -6.2% | 98,441 | +20.2% | 0.28% | -23.1% |
| Q2 2021 | $5,296,000 | +70.6% | 81,891 | +50.6% | 0.36% | -18.8% |
| Q1 2021 | $3,105,000 | +24.8% | 54,375 | +49.2% | 0.45% | +56.1% |
| Q4 2020 | $2,488,000 | – | 36,438 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |